Overview

Bupivacaine HCl PK and Safety in Augmentation Mammoplasty

Status:
Completed
Trial end date:
2018-11-05
Target enrollment:
Participant gender:
Summary
This is a Phase 4, randomized, open-label study of bupivacaine HCl administered either by instillation into the surgical site or by injection into the surgical site in subjects undergoing bilateral submuscular augmentation mammoplasty under general anesthesia.
Phase:
Phase 4
Details
Lead Sponsor:
Heron Therapeutics
Treatments:
Bupivacaine